Boiron S.A. (BOIRF) Stock

About Boiron S.A.

Boiron S.A. is a leading pharmaceutical enterprise focused on the global development and sale of homeopathic treatments. Its market presence extends across France, the wider European continent, North America, and numerous international territories. The company's offerings comprise a diverse array of homeopathic products, including both non-proprietary and branded formulations. Notable examples from its brand portfolio target specific health concerns: Oscillococcinum is formulated to alleviate symptoms associated with influenza, such as fever, chills, headaches, and general body aches. Stodal and Stodaline are designed for the symptomatic relief of coughs. Arnigel provides topical support for minor, non-open traumatic injuries. Camilia is specifically developed to soothe teething discomfort in infants. Sédatif PC addresses anxiety, emotional imbalances, and mild sleep disturbances. Coryzalia helps manage cold symptoms and rhinitis. Homéoptic offers relief for various types of eye irritation and discomfort in both adults and children. Homéovox is aimed at vocal disorders. Beyond its core homeopathic line, Boiron provides a range of supplementary health products. These include dietary supplements; the Dermoplasmine collection (available as stick, balm, and mousse) for dry lips and skin; Mag' Nuit, designed to aid sleep; Arnitrosium for joint pain; Castor Equi Boiron ointment to treat cracked skin; and Storinil, a syrup for cold treatment. Furthermore, the company produces herbal medicines, such as Canephron, which supports increased urine production and improved urinary elimination. Its product list also features moisturizing baby milk and a selection of medical devices, including COVID-19 self-tests and rapid antigenic tests. Boiron distributes its extensive product portfolio through a wide network, encompassing its own distribution centers, independent pharmacies, large pharmacy chains, wholesalers, grocery stores, specialized health food retailers, and online sales platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.

Boiron S.A. is headquartered in FR.

Boiron S.A. (BOIRF) stock trades at $31.50 with a market capitalization of $546.91M. The stock is valued at a price-to-earnings (P/E) ratio of 14.78, price-to-book of 1.24, price-to-sales of 0.95. Over the past 52 weeks the stock has ranged between $24.00 and $32.28, and currently trades 2.4% below its 52-week high. It pays a dividend yielding 4.98%.

On profitability, Boiron S.A. generates a return on equity (ROE) of 8.57%, return on capital employed of 7.52%, an operating margin of 7.06%, a net profit margin of 6.51%.

Official website: www.boiron.fr